Skip to main content

Our Technology

Next-Generation Delivery Technology

Psycheceutical's patented NeuroDirect™ non-systemic delivery technology is designed to deliver neuro-active compounds directly into the nerve tissue via topical application at the back of the neck.

This unique delivery system is intended to enable immediate and sustained drug delivery, with safe dosage control, and consistent results, while avoiding the GI tract and any unwanted side effects that may come from toxicity.

We believe this technology will enable patients to receive medication in a way that reduces or mitigates entirely the systemic side effects of psychedelic compounds, such as hallucinations, nausea, and toxicity, potentially opening a new world to mental health treatment.


Non-Systemic Drug Delivery Technology

The process we are targeting is:

  • Applied through a topical compound at the back of the neck at the hairline

  • Penetrates the peripheral nerve endings that travel along the spinal cord, to provide a direct avenue to neural tissue within the brain

  • Nerve endings travel along the spinal cord

  • Bypasses the blood-brain barrier

  • Facilitates quick response time while avoiding unwanted side effects

NeuroDirect™ Non-Systemic Drug Delivery Technology Goals


Direct Delivery

Delivery to introduce neuro-affective agents directly into nerve tissue, designed to result in much lower dosing and excreted components.

Improved Efficacy

Follow nerve pathways to the target tissue to allow for improved efficacy of the active compound and immediate action in minutes.

Rapid Symptom Reduction

NeuroDirect™ delivery has shown to produce symptom reduction in as little as 10-15 minutes.*

Minimize Adverse Reactions

NeuroDirect™ lower dosage delivery has shown symptom reduction without significant adverse reactions*.

Reduce Psychedelic Effects

Reduce or mitigate entirely the systemic side effects of psychedelic compounds, such as hallucinations, nausea, and toxicity, opening an entire new approach to neuro-therapeutics.

Reduce Drug Toxicity

Limit undesired non-targeted distribution throughout the body, vastly reducing exposure to drug toxicities and side effects.

*Data from a non-GCP observational study to be used solely as support for future drug approval. Complete efficacy/safety will be fully delineated in GCP pivotal clinical trials.

Explore Our Drug

Development Pipeline


Fill out the form below to get updates delivered directly to your inbox.